Quoin Pharmaceuticals, Ltd. (QNRX) Stock Analysis

Company Overview

Quoin Pharmaceuticals, Ltd. operates as a late-stage specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products specifically for rare and orphan diseases within the United States. The company functions within the Healthcare sector and the Biotechnology industry, a classification that defines its focus on scientific research and the production of biological medicines rather than traditional small-molecule drugs. Currently, the enterprise maintains a market capitalization of $10.36M, while specific figures for annual revenue and employee count are not disclosed in the available data. These valuation metrics indicate that Quoin Pharmaceuticals, Ltd. operates as a micro-cap entity, suggesting a relatively small market presence typical of early-to-mid stage biotechnology firms that are heavily invested in product development rather than widespread commercial sales.

Financial Health

The company reports a net income of $-15,804,655 over the trailing twelve months, accompanied by an EBITDA of $-16,190,716, while specific revenue figures are not provided in the current dataset. The substantial gap between the reported net income and the near-identical EBITDA figures reveals a cost structure where interest expenses, taxes, or other non-operating costs are minimal relative to the massive operating losses, a common characteristic in capital-intensive biotechnology development phases. Free cash flow is not reported for the company, which implies that the firm is currently burning cash to fund its research and development activities rather than generating positive operating cash flow. The company holds a cash reserve of $18.75M against total debt of $2.32M, resulting in a debt-to-equity ratio of 17.71. Although the debt-to-equity ratio appears high numerically, the absolute debt load is low compared to the substantial cash on hand, suggesting a balance sheet that is more liquidity-driven than leverage-driven despite the metric. The current ratio stands at 3.61, which indicates a strong ability to meet short-term obligations with its liquid assets. Return on Equity is recorded at -141.6% and Return on Assets at -56.4%, metrics that reveal that management is currently utilizing shareholder capital to generate negative returns, consistent with the strategy of reinvesting funds into product development before commercialization begins.

Valuation Assessment

The trailing twelve-month P/E ratio is not available due to the company's lack of net income, whereas the forward P/E is listed as -2.03, implying that analysts project earnings that are still negative in the near term. The price-to-book ratio is 0.73, indicating that the market values the company at a discount to its net asset value, a common valuation characteristic for biotechnology firms with significant intangible assets that are not fully captured on the balance sheet. The price-to-sales ratio and EV/EBITDA multiple of -19.75 are not available or negative, respectively, suggesting that traditional valuation multiples based on profitability are not applicable at this stage of the company's lifecycle. The stock has traded between a 52-week low of $5.01 and a 52-week high of $41.80. Without a specific current share price provided in the facts, the range indicates significant volatility, with the stock potentially trading anywhere within this wide band depending on market sentiment regarding its pipeline. The beta value is not available, so the specific level of price volatility relative to the broader market cannot be quantified based on the provided data.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are not reported as the company has not yet achieved positive revenue streams in a manner that allows for standard growth rate calculations. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue, as both metrics are currently non-existent or not disclosed. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, meaning the payout ratio is effectively 0.0% and all available earnings are theoretically reinvested into growth initiatives rather than distributed to shareholders. The overall growth and income profile is defined by a lack of current income generation and a focus on future product potential rather than existing cash flow or dividend stability.